Myriad Genetics, Inc.
MYGN
$3.05
-$0.15-4.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -3.16% | -0.28% | -1.56% | 0.21% | 3.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.16% | -0.28% | -1.56% | 0.21% | 3.83% |
| Cost of Revenue | 2.11% | -0.12% | -1.70% | -3.74% | -0.81% |
| Gross Profit | -5.37% | -0.34% | -1.50% | 1.97% | 5.90% |
| SG&A Expenses | -1.75% | -3.24% | -4.10% | -2.49% | -1.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.36% | -2.96% | -3.59% | -1.25% | 0.44% |
| Operating Income | -18.15% | 27.98% | 22.87% | 13.85% | 25.85% |
| Income Before Tax | 73.40% | -215.05% | -220.18% | -264.75% | -168.39% |
| Income Tax Expenses | 103.19% | 100.39% | -848.72% | -4,033.33% | -1,692.86% |
| Earnings from Continuing Operations | 71.51% | -294.38% | -187.43% | -245.26% | -154.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.51% | -294.38% | -187.43% | -245.26% | -154.64% |
| EBIT | -18.15% | 27.98% | 22.87% | 13.85% | 25.85% |
| EBITDA | -127.68% | 57.73% | 47.19% | 22.49% | 63.88% |
| EPS Basic | 72.02% | -286.80% | -181.58% | -233.51% | -137.30% |
| Normalized Basic EPS | -26.57% | 19.90% | 15.56% | 12.22% | 27.06% |
| EPS Diluted | 71.93% | -286.11% | -181.02% | -232.38% | -136.56% |
| Normalized Diluted EPS | -26.57% | 19.90% | 15.56% | 12.22% | 27.06% |
| Average Basic Shares Outstanding | 2.46% | 2.36% | 2.15% | 2.97% | 4.99% |
| Average Diluted Shares Outstanding | 2.46% | 2.36% | 2.15% | 2.97% | 4.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |